Evidence map›Paper›PMID 32289352›Full record

Trial reportJournal of clinical epidemiology2020

The adapted Zelen was a feasible design to trial exercise in myeloma survivors.

Joanne Land, Orla McCourt, Malgorzata Heinrich, Rebecca J Beeken, Dimitrios A Koutoukidis, Bruce Paton, Kwee Yong, Allan Hackshaw, Abigail Fisher

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Joanne LandDepartment of Behavioural Science and Health, University College London, WC1E 7HB, London, UK.
Orla McCourtDepartment of Behavioural Science and Health, University College London, WC1E 7HB, London, UK; Research Department of Haematology, Cancer Institute, University College London, London, UK; University College London Hospitals NHS Foundation Trust, London, UK.
Malgorzata HeinrichDepartment of Behavioural Science and Health, University College London, WC1E 7HB, London, UK.
Rebecca J BeekenLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Dimitrios A KoutoukidisDepartment of Behavioural Science and Health, University College London, WC1E 7HB, London, UK; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Bruce PatonInstitute of Sport Exercise & Health, London, UK.
Kwee YongResearch Department of Haematology, Cancer Institute, University College London, London, UK.
Allan HackshawCancer Research UK & UCL Cancer Trials Centre, University College London, London, UK.
Abigail FisherDepartment of Behavioural Science and Health, University College London, WC1E 7HB, London, UK. Electronic address: abigail.fisher@ucl.ac.uk.
University College London · GBEnglish Institute of Sport · GBOxford BioMedica (United Kingdom) · GBUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Leeds · GB

Funding

Cancer Research UK 14133Cancer Research UK 27498Cancer Research UK C1418/A14133Department of Health ICA-CDRF-2017-03-067
6 · The paper itself

Abstract

objectivesWe used a method rarely seen in cancer behavioral trials to explore methods of overcoming difficulties often seen in randomized controlled trials. We report our experiences of the adapted Zelen design, so that other researchers can consider this approach for behavioral trials. STUDY DESIGN AND

settingThe adapted Zelen design was used to explore the effects of exercise on multiple myeloma patients fatigue, quality of life, and physical outcomes. All participants consented to an observational cohort study of lifestyle factors but were unaware of subsequent randomization to remain in cohort only group or be offered an exercise intervention requiring second consent.

resultsThere was lower than expected uptake to the exercise offered group (57%), so the length of recruitment increased from 24 to 29 months to ensure power was reached. At enrollment, patients were unaware of the potential increased commitment, and as a result, 62% of participants allocated to the intervention declined because of the extra time/travel commitment required. This emulates clinical settings and suggests improvements in intervention delivery are required. Our findings suggest that the adapted Zelen design may be useful in limiting dropout of controls due to dissatisfaction from group allocation, or contamination of control arm.

conclusionFuture use of this design warrants careful consideration of the study resources and recruitment time frames required but holds potential value in reducing contamination, control group dissatisfaction, and resulting dropout. Adapted Zelen design reduces selection bias and therefore gives clinicians a better understanding of acceptability in clinical settings. Future studies should evaluate control group experiences of the design and formally record contamination throughout the study to confirm its acceptability.

Indexed as

Cancer SurvivorsExercise TherapyMultiple MyelomaQuality of LifeCohort StudiesFeasibility StudiesFemaleHumansInformed ConsentMalePatient SatisfactionPatient SelectionRandom AllocationResearch DesignExerciseExercise-oncologyMultiple myelomaPhysical activityPost randomization consentResearch design

Identifiers

PMID32289352
PMCPMC7482584
OpenAlexW3015723274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.